Revolution Medicines Billion Market: Why the Valuation Makes Sense
A biotech with no current revenue can still carry a sky-high valuation. This article explains how Revolution Medicine...
Target discretionary areas first, compare frequent bills, and negotiate rates to reduce outflows while maintaining needs.
14,378 articlesA biotech with no current revenue can still carry a sky-high valuation. This article explains how Revolution Medicine...
SpaceX’s rapid Nasdaq-100 inclusion could redraw the ETF landscape. This guide explains what changes to expect, how i...
As AI workloads expand, data center power stocks are seeing a fresh wave of orders and upgraded guidance. This report...
Kick off the week with a curated set of monday reads designed for busy investors. Explore macro signals, fixed income...
Big AI-driven demand is reshaping data-center stocks. Terawulf and IREN rallied as investors priced in new compute ca...
A USMCA review is on the radar as supply chains evolve and tariffs shift. This article breaks down why extending the ...
Broadcom inks a long-term extension with Apple through 2031, tying roughly 20% of AVGO's annual sales to the iPhone m...
A new Federal Reserve briefing warns that hidden tariff costs are shaping consumer prices and policy decisions. Inves...
SoFi is pursuing growth beyond lending with AI-powered tools. This article explores whether AI agents could be the ne...
A small tech firm is rethinking its core business, moving from crypto mining to powering AI clouds. This growth phase...
In a striking move, trump’s crypto disclosure exposes how policy signals and private crypto stakes collide at the hig...
Palantir is moving beyond a services banner toward a durable AI-first platform. If the company scales its AI plumbing...